Gujarat Themis Biosyn Ltd manufactures and sells finished Active Pharmaceutical Ingredients products by fermentation processBusiness Overview Company manufactures pharmaceuticals and medicinal chemicals. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary). GTBL entered into Technical & Financial collaboration with Yuhan Corporation, South Korea, and...
Gujarat Themis Biosyn (GTBL) kicked off Q1 FY27 with strong results. Revenue climbed 22.1% YoY to Rs. 43.8 Cr, driven by healthy sales volumes. EBITDA surged 49.4% to Rs. 20.8 Cr, with PAT up 22.1% to Rs. 11.1 Cr, leading to an EPS of Rs. 1.02. Management noted improved margins...
Gujarat Themis Biosyn (GTBL) is actively transforming into a diversified pharma platform. **Business Performance:** GTBL's core fermentation capacity doubled to 990 KL in FY26. FY26 revenue hit INR 165.82 Cr (up from INR 150.80 Cr in FY25), though slightly below FY24. PAT for FY26 was INR 46.68 Cr, declining from...
**Gujarat Themis Biosyn Q4 & FY26 Update:** The company closed FY26 strong, with Q4 revenue up 17% YoY to Rs. 44.2 Cr and EBITDA up 20.7% to Rs. 19.4 Cr. For the full year, revenue grew nearly 10% to Rs. 165.8 Cr and EBITDA rose 9.7% to Rs. 75.5 Cr....
Gujarat Themis Biosyn (GTBL) is acquiring 100% equity in MicroBiopharm Japan (MBJ) for approximately INR 1,300 Cr, funded by an optimal mix of debt and equity. This transaction is expected to close by Q2 FY2027 and be EPS accretive. MBJ, with over 60 years of experience and three GMP-compliant plants,...
**Recent Developments:** Gujarat Themis Biosyn (GTBL) is set to acquire Sanofi's global Anti-TB and Anti-Infective product portfolio, a strategic asset acquisition valued at approximately EURO 158 million. This includes 13 established brands, marketing authorizations, and inventory, reaching over 55 countries. **Business Performance:** The acquired portfolio generated ~EURO 62 million in...
